NCT00803816

Everolimus for the Treatment of Uveitis Unresponsive to Cyclosporine A

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Carsten Heinz · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Study efficacy of everolimus on course of uveitis: * obtain quiescence of inflammation after start of treatment * duration to obtain quiescence of inflammation * number of patients with quiescence of inflammation

Detailed description

occurence of new complications from uveitis * course of visual acuity (LogMAR): percentage of patients with visual loss of 10 or more numbers on ETDRS as compared to baseline * change of recurrence rate as compared to time before everolimus treatment * occurence of recurrence after obtaining remission with everolimus treatment * duration to occurence of recurrence o number of patients with recurrence * corticosparing effect from everolimus * number of patients without topical corticosteroids; number of patients with reduced topical corticosteroids (\<3x/daily) * number of patients without systemic corticosteroids; number of patients with reduced systemic corticosteroids (\<10mg/daily) * efficacy of uveitis within 12 months * maintenance of remission after withdrawel of everolimus treatment at 12 months o course of cystoid macula edema (FLA, OCT)

Conditions

• Uveitis

Interventions

Type	Name	Description
DRUG	everolimus	everolimus 1.0 - 2.5mg oral daily dosage

Timeline

• Start date: 2007-11-01
• Primary completion: 2010-09-01
• Completion: 2010-12-01
• First posted: 2008-12-08
• Last updated: 2015-05-27

Locations

1 site across 1 country: Germany